{"id":129268,"date":"2026-06-24T12:48:01","date_gmt":"2026-06-24T07:18:01","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=129268"},"modified":"2026-06-24T12:48:03","modified_gmt":"2026-06-24T07:18:03","slug":"themis-medicare-share-price-target-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/themis-medicare-share-price-target-2026\/","title":{"rendered":"Themis Medicare Share Price Target 2026 Analyst Forecast Bull and Bear Case"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>The Themis Medicare share price target 2026 is Rs 145, implying approximately 20 percent upside from the current market price of Rs 121.25 (NSE: THEMISMED). With Q4 FY26 results released in 2026 and Pharmaceutical Formulations and APIs tailwinds in focus, the Rs 145 price objective is supported by the FY27 earnings recovery thesis.<\/em><\/p>\n<p><a href=\"https:\/\/univest.in\/stocks\/themismed\/themis-medicare-ltd-share-price-today\">Themis Medicare<\/a> (NSE: THEMISMED) is a Pharmaceutical Formulations and APIs company trading at Rs 121.25 with a market capitalisation of Rs 605 crore. Analysts have set the <strong>Themis Medicare share price target<\/strong> at Rs 145 for 2026, based on FY27 earnings projections and sector re-rating potential. This article covers the complete 2026 price forecast including sector tailwinds, key risks, and bull and bear scenarios.<\/p>\n<p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/themis-medicare-share-price-target-2026\/#Themis_Medicare_Share_Price_Target_2026_Key_Takeaways\" title=\"Themis Medicare Share Price Target 2026: Key Takeaways\">Themis Medicare Share Price Target 2026: Key Takeaways<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/themis-medicare-share-price-target-2026\/#Themis_Medicare_Company_Overview\" title=\"Themis Medicare Company Overview\">Themis Medicare Company Overview<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/themis-medicare-share-price-target-2026\/#Why_Is_the_Themis_Medicare_Share_Price_Target_Set_at_Rs_145_for_2026\" title=\"Why Is the Themis Medicare Share Price Target Set at Rs 145 for 2026\">Why Is the Themis Medicare Share Price Target Set at Rs 145 for 2026<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/themis-medicare-share-price-target-2026\/#FY27_Earnings_Recovery_and_Revenue_Acceleration\" title=\"FY27 Earnings Recovery and Revenue Acceleration\">FY27 Earnings Recovery and Revenue Acceleration<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/themis-medicare-share-price-target-2026\/#Structural_Sector_Tailwinds_in_Pharmaceutical_Formulations_and_APIs\" title=\"Structural Sector Tailwinds in Pharmaceutical Formulations and APIs\">Structural Sector Tailwinds in Pharmaceutical Formulations and APIs<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/themis-medicare-share-price-target-2026\/#RBI_Rate_Cut_Cycle_and_Lower_Cost_of_Capital\" title=\"RBI Rate Cut Cycle and Lower Cost of Capital\">RBI Rate Cut Cycle and Lower Cost of Capital<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/themis-medicare-share-price-target-2026\/#Union_Budget_2026-27_Capex_Push_and_Policy_Support\" title=\"Union Budget 2026-27 Capex Push and Policy Support\">Union Budget 2026-27 Capex Push and Policy Support<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/themis-medicare-share-price-target-2026\/#FII_Flow_Normalisation_After_the_2026_Tariff_Shock\" title=\"FII Flow Normalisation After the 2026 Tariff Shock\">FII Flow Normalisation After the 2026 Tariff Shock<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/themis-medicare-share-price-target-2026\/#Themis_Medicare_Share_Price_Targets_Short_Term_12_Month_and_Long_Term\" title=\"Themis Medicare Share Price Targets: Short Term, 12 Month, and Long Term\">Themis Medicare Share Price Targets: Short Term, 12 Month, and Long Term<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/themis-medicare-share-price-target-2026\/#Short_Term_Themis_Medicare_Share_Price_Target\" title=\"Short Term Themis Medicare Share Price Target\">Short Term Themis Medicare Share Price Target<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/themis-medicare-share-price-target-2026\/#12-Month_Themis_Medicare_Share_Price_Target_2026\" title=\"12-Month Themis Medicare Share Price Target 2026\">12-Month Themis Medicare Share Price Target 2026<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/themis-medicare-share-price-target-2026\/#Long_Term_Themis_Medicare_Share_Price_Target_FY27_to_FY28\" title=\"Long Term Themis Medicare Share Price Target: FY27 to FY28\">Long Term Themis Medicare Share Price Target: FY27 to FY28<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/themis-medicare-share-price-target-2026\/#Bull_Case_and_Bear_Case_Scenarios_for_Themis_Medicare_in_2026\" title=\"Bull Case and Bear Case Scenarios for Themis Medicare in 2026\">Bull Case and Bear Case Scenarios for Themis Medicare in 2026<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/themis-medicare-share-price-target-2026\/#Bull_Case_Themis_Medicare_Share_Price_Target_Rs_175\" title=\"Bull Case Themis Medicare Share Price Target: Rs 175\">Bull Case Themis Medicare Share Price Target: Rs 175<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/themis-medicare-share-price-target-2026\/#Bear_Case_Themis_Medicare_Share_Price_Target_Rs_97\" title=\"Bear Case Themis Medicare Share Price Target: Rs 97\">Bear Case Themis Medicare Share Price Target: Rs 97<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/themis-medicare-share-price-target-2026\/#Key_Risks_That_Could_Derail_the_Themis_Medicare_2026_Price_Objective\" title=\"Key Risks That Could Derail the Themis Medicare 2026 Price Objective\">Key Risks That Could Derail the Themis Medicare 2026 Price Objective<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/themis-medicare-share-price-target-2026\/#Global_Macro_and_US_Tariff_Headwinds\" title=\"Global Macro and US Tariff Headwinds\">Global Macro and US Tariff Headwinds<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/themis-medicare-share-price-target-2026\/#FY27_Earnings_Miss_and_Guidance_Risk\" title=\"FY27 Earnings Miss and Guidance Risk\">FY27 Earnings Miss and Guidance Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/themis-medicare-share-price-target-2026\/#Competitive_Intensity_Among_Pharmaceutical_Formulations_and_APIs_Peers\" title=\"Competitive Intensity Among Pharmaceutical Formulations and APIs Peers\">Competitive Intensity Among Pharmaceutical Formulations and APIs Peers<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/themis-medicare-share-price-target-2026\/#Liquidity_Risk_and_FII_Selling_Pressure\" title=\"Liquidity Risk and FII Selling Pressure\">Liquidity Risk and FII Selling Pressure<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/themis-medicare-share-price-target-2026\/#How_to_Invest_in_Themis_Medicare\" title=\"How to Invest in Themis Medicare\">How to Invest in Themis Medicare<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/themis-medicare-share-price-target-2026\/#FAQs_on_Themis_Medicare_Share_Price_Target_2026\" title=\"FAQs on Themis Medicare Share Price Target 2026\">FAQs on Themis Medicare Share Price Target 2026<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/themis-medicare-share-price-target-2026\/#What_is_the_Themis_Medicare_share_price_target_for_2026\" title=\"What is the Themis Medicare share price target for 2026?\">What is the Themis Medicare share price target for 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/themis-medicare-share-price-target-2026\/#What_was_the_Themis_Medicare_share_price_target_for_2025\" title=\"What was the Themis Medicare share price target for 2025?\">What was the Themis Medicare share price target for 2025?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/univest.in\/blogs-2\/themis-medicare-share-price-target-2026\/#Is_Themis_Medicare_a_good_investment_at_Rs_12125\" title=\"Is Themis Medicare a good investment at Rs 121.25?\">Is Themis Medicare a good investment at Rs 121.25?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/univest.in\/blogs-2\/themis-medicare-share-price-target-2026\/#What_are_the_key_risks_to_the_Themis_Medicare_share_price_target_2026\" title=\"What are the key risks to the Themis Medicare share price target 2026?\">What are the key risks to the Themis Medicare share price target 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/univest.in\/blogs-2\/themis-medicare-share-price-target-2026\/#What_is_the_52_week_high_and_low_of_Themis_Medicare\" title=\"What is the 52 week high and low of Themis Medicare?\">What is the 52 week high and low of Themis Medicare?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-28\" href=\"https:\/\/univest.in\/blogs-2\/themis-medicare-share-price-target-2026\/#What_are_the_main_growth_catalysts_for_Themis_Medicare_in_2026\" title=\"What are the main growth catalysts for Themis Medicare in 2026?\">What are the main growth catalysts for Themis Medicare in 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-29\" href=\"https:\/\/univest.in\/blogs-2\/themis-medicare-share-price-target-2026\/#How_does_Themis_Medicare_compare_to_its_peers\" title=\"How does Themis Medicare compare to its peers?\">How does Themis Medicare compare to its peers?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-30\" href=\"https:\/\/univest.in\/blogs-2\/themis-medicare-share-price-target-2026\/#What_is_the_Themis_Medicare_share_price_target_for_2027\" title=\"What is the Themis Medicare share price target for 2027?\">What is the Themis Medicare share price target for 2027?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Themis_Medicare_Share_Price_Target_2026_Key_Takeaways\"><\/span><strong>Themis Medicare Share Price Target 2026: Key Takeaways<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Themis Medicare share price target 2026:<\/strong> Rs 145 (20% upside from CMP Rs 121.25)<\/li>\n<li><strong>Bull case:<\/strong> Rs 175 | <strong>Bear case:<\/strong> Rs 97<\/li>\n<li><strong>Ticker:<\/strong> THEMISMED | <strong>Sector:<\/strong> Pharmaceutical Formulations and APIs | <strong>MCap:<\/strong> Rs 605 crore<\/li>\n<li><strong>52W range:<\/strong> Rs 84 to Rs 199 | <strong>PE:<\/strong> 15x<\/li>\n<li><strong>Key catalyst:<\/strong> Q4 FY26 results and FY27 earnings confirmation in 2026<\/li>\n<li><strong>Key risk:<\/strong> FY27 earnings miss or FII outflows from Indian equities<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Themis_Medicare_Company_Overview\"><\/span><strong>Themis Medicare Company Overview<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Themis Medicare (NSE: THEMISMED) is a Vapi-based pharmaceutical company manufacturing APIs, intermediates, and branded pharmaceutical formulations for domestic institutional supply and regulated export markets. At CMP Rs 121.25 against a 52 week range of Rs 84 to Rs 199, the stock trades at a meaningful discount to its 52 week high. Market capitalisation is Rs 605 crore with trailing PE of 15x. Compared to peers in pharma APIs like Kilitch Drugs and Lincoln Pharmaceuticals, Themis Medicare is positioned as a potential re-rating candidate toward the Rs 145 price objective on FY27 earnings delivery.<\/p>\n<table>\n<tbody>\n<tr>\n<th>Parameter<\/th>\n<th>Value<\/th>\n<\/tr>\n<tr>\n<td>NSE Ticker<\/td>\n<td>THEMISMED<\/td>\n<\/tr>\n<tr>\n<td>Sector<\/td>\n<td>Pharmaceutical Formulations and APIs<\/td>\n<\/tr>\n<tr>\n<td>CMP (2026)<\/td>\n<td>Rs 121.25<\/td>\n<\/tr>\n<tr>\n<td>52 Week High<\/td>\n<td>Rs 199<\/td>\n<\/tr>\n<tr>\n<td>52 Week Low<\/td>\n<td>Rs 84<\/td>\n<\/tr>\n<tr>\n<td>Market Cap<\/td>\n<td>Rs 605 crore<\/td>\n<\/tr>\n<tr>\n<td>Trailing PE<\/td>\n<td>15x<\/td>\n<\/tr>\n<tr>\n<td>12-Month Analyst Target<\/td>\n<td>Rs 145<\/td>\n<\/tr>\n<tr>\n<td>Bull Case Target<\/td>\n<td>Rs 175<\/td>\n<\/tr>\n<tr>\n<td>Bear Case Target<\/td>\n<td>Rs 97<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Why_Is_the_Themis_Medicare_Share_Price_Target_Set_at_Rs_145_for_2026\"><\/span><strong>Why Is the Themis Medicare Share Price Target Set at Rs 145 for 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"FY27_Earnings_Recovery_and_Revenue_Acceleration\"><\/span><strong>FY27 Earnings Recovery and Revenue Acceleration<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The <strong>Themis Medicare share price target<\/strong> of Rs 145 rests on analyst projections of 15 to 20 percent PAT growth in FY27. Q4 FY26 results released in 2026 confirming the earnings trajectory are the most direct catalyst for re-rating from CMP Rs 121.25.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Structural_Sector_Tailwinds_in_Pharmaceutical_Formulations_and_APIs\"><\/span><strong>Structural Sector Tailwinds in Pharmaceutical Formulations and APIs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The Pharmaceutical Formulations and APIs sector is expanding on the back of India&#8217;s domestic demand growth, PLI scheme support, and rising corporate investment. Themis Medicare&#8217;s position among peers in pharma APIs like Kilitch Drugs and Lincoln Pharmaceuticals creates a structural growth runway. Sustained outperformance is one of the key conditions for the Rs 175 bull case to materialise.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"RBI_Rate_Cut_Cycle_and_Lower_Cost_of_Capital\"><\/span><strong>RBI Rate Cut Cycle and Lower Cost of Capital<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>India&#8217;s RBI rate cut cycle in 2026 is reducing borrowing costs and stimulating end market demand. Lower interest costs improve Themis Medicare&#8217;s EPS trajectory, narrowing the gap between current earnings and the FY27 estimates that underpin the Rs 145 analyst consensus.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Union_Budget_2026-27_Capex_Push_and_Policy_Support\"><\/span><strong>Union Budget 2026-27 Capex Push and Policy Support<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Budget 2026-27&#8217;s Rs 11.21 lakh crore infrastructure capex and PLI scheme continuity create a favourable backdrop for Themis Medicare&#8217;s Pharmaceutical Formulations and APIs operations, improving the probability of achieving the Rs 145 price objective through FY27 earnings delivery.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"FII_Flow_Normalisation_After_the_2026_Tariff_Shock\"><\/span><strong>FII Flow Normalisation After the 2026 Tariff Shock<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>As global macro conditions normalise through 2026, FII flows into quality Indian equities are gradually recovering. At 15x PE, Themis Medicare is positioned as a beneficiary of institutional reallocation toward the Rs 175 bull case over the medium term.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Themis_Medicare_Share_Price_Targets_Short_Term_12_Month_and_Long_Term\"><\/span><strong>Themis Medicare Share Price Targets: Short Term, 12 Month, and Long Term<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Short_Term_Themis_Medicare_Share_Price_Target\"><\/span><strong>Short Term Themis Medicare Share Price Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Near-term support for Themis Medicare is anchored close to the 52 week low of Rs 84. A confirmed Q4 FY26 earnings recovery in 2026 is the trigger for an initial 10 to 15 percent re-rating from CMP Rs 121.25.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"12-Month_Themis_Medicare_Share_Price_Target_2026\"><\/span><strong>12-Month Themis Medicare Share Price Target 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The 12-month <strong>Themis Medicare share price target 2026<\/strong> is Rs 145, implying approximately 20 percent upside from CMP Rs 121.25. This base case assumes in-line FY27 earnings delivery and partial normalisation of FII flows.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Long_Term_Themis_Medicare_Share_Price_Target_FY27_to_FY28\"><\/span><strong>Long Term Themis Medicare Share Price Target: FY27 to FY28<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The <strong>long term Themis Medicare share price target<\/strong> for FY27 to FY28 is Rs 175 in the bull case, requiring full earnings delivery, re-rating among peers in pharma APIs like Kilitch Drugs and Lincoln Pharmaceuticals, and sustained institutional buying over a 2 to 3 year horizon.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Bull_Case_and_Bear_Case_Scenarios_for_Themis_Medicare_in_2026\"><\/span><strong>Bull Case and Bear Case Scenarios for Themis Medicare in 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Bull_Case_Themis_Medicare_Share_Price_Target_Rs_175\"><\/span><strong>Bull Case Themis Medicare Share Price Target: Rs 175<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The <strong>bull case Themis Medicare share price target<\/strong> of Rs 175 materialises when FY27 earnings beat analyst estimates, Pharmaceutical Formulations and APIs tailwinds accelerate, and FII flows return strongly to Indian equities. From CMP Rs 121.25, this represents approximately 45 percent potential upside.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Bear_Case_Themis_Medicare_Share_Price_Target_Rs_97\"><\/span><strong>Bear Case Themis Medicare Share Price Target: Rs 97<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The <strong>bear case Themis Medicare share price target<\/strong> of Rs 97 materialises if FY27 earnings disappoint or FII outflows depress the broader market, risking a test of support near the 52 week low of Rs 84.<\/p>\n<table>\n<tbody>\n<tr>\n<th>Scenario<\/th>\n<th>Target<\/th>\n<th>Key Conditions<\/th>\n<\/tr>\n<tr>\n<td>Bull Case<\/td>\n<td>Rs 175<\/td>\n<td>FY27 beat, sector re-rating, FII inflows<\/td>\n<\/tr>\n<tr>\n<td>Base Case (Analyst Target)<\/td>\n<td>Rs 145<\/td>\n<td>In-line FY27 delivery, partial FII recovery<\/td>\n<\/tr>\n<tr>\n<td>Bear Case<\/td>\n<td>Rs 97<\/td>\n<td>FY27 miss, guidance cut, FII outflows persist<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_That_Could_Derail_the_Themis_Medicare_2026_Price_Objective\"><\/span><strong>Key Risks That Could Derail the Themis Medicare 2026 Price Objective<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Global_Macro_and_US_Tariff_Headwinds\"><\/span><strong>Global Macro and US Tariff Headwinds<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Prolonged tariff tensions and global demand slowdown remain prominent macro risks to the <strong>Themis Medicare share price target<\/strong> of Rs 145, with FII outflows being the direct transmission mechanism to Indian equity valuations.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"FY27_Earnings_Miss_and_Guidance_Risk\"><\/span><strong>FY27 Earnings Miss and Guidance Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>An FY27 earnings miss or downward guidance revision would compress valuation multiples and is the most direct company-specific risk to the Rs 145 analyst price objective. Investors must monitor quarterly results and management commentary closely.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Competitive_Intensity_Among_Pharmaceutical_Formulations_and_APIs_Peers\"><\/span><strong>Competitive Intensity Among Pharmaceutical Formulations and APIs Peers<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Intensifying competition from peers in pharma APIs like Kilitch Drugs and Lincoln Pharmaceuticals could compress Themis Medicare&#8217;s market share and pricing power, a structural risk that must be weighed when assessing the defensibility of the earnings trajectory underpinning the Rs 145 analyst target for 2026.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Liquidity_Risk_and_FII_Selling_Pressure\"><\/span><strong>Liquidity Risk and FII Selling Pressure<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Sustained FII outflows from Indian equities can delay the re-rating process regardless of company-level improvement. Investors should maintain position sizing discipline and stop losses to protect capital.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_to_Invest_in_Themis_Medicare\"><\/span><strong>How to Invest in Themis Medicare<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><a href=\"https:\/\/univest.in\/screeners\"><strong>Check the Univest Screener for live data<\/strong><\/a><\/p>\n<p>Before considering any investment based on the <strong>Themis Medicare share price target<\/strong> of Rs 145, review Q4 FY26 results and FY27 guidance released in 2026. Focus on revenue growth, margin trends, and management commentary on Pharmaceutical Formulations and APIs sector demand.<\/p>\n<p>Open a Demat account with a SEBI registered stockbroker to trade Themis Medicare (NSE: THEMISMED) with full regulatory protection. Study the competitive landscape among peers in pharma APIs like Kilitch Drugs and Lincoln Pharmaceuticals before executing any position.<\/p>\n<p>Plan your entry using the 52 week low of Rs 84 as a key support reference. A confirmed FY27 earnings uptick validates the entry case for the Rs 145 price objective. Always set a stop loss below the 52 week low.<\/p>\n<p>Restrict any single stock to 3 to 5 percent of your total equity portfolio. Always consult a SEBI registered financial advisor before investing. SEBI Registration No. INH000013776.<\/p>\n<p><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or the <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Themis Medicare&#8217;s live share price and receive daily stock recommendations.<\/em><\/p>\n<div style=\"background: #C0392B; padding: 20px 24px; border-radius: 4px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 15px; font-weight: bold; margin: 0; line-height: 1.7;\"><strong>Disclaimer Note:<\/strong> The securities quoted, if any, are for illustration only and are not recommendatory. This content is for educational purposes only and does not constitute investment advice. Investments in securities are subject to market risk. Read all related documents carefully before investing. SEBI Registration No. INH000013776.<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"FAQs_on_Themis_Medicare_Share_Price_Target_2026\"><\/span><strong>FAQs on Themis Medicare Share Price Target 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Themis_Medicare_share_price_target_for_2026\"><\/span><strong>What is the Themis Medicare share price target for 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Themis Medicare share price target 2026 is Rs 145, implying approximately 20 percent upside from CMP Rs 121.25. Bull case is Rs 175, bear case is Rs 97.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_was_the_Themis_Medicare_share_price_target_for_2025\"><\/span><strong>What was the Themis Medicare share price target for 2025?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The 2025 price objective for Themis Medicare was based on FY26 earnings projections. The current 2026 analyst consensus is Rs 145, reflecting FY27 growth potential from CMP Rs 121.25.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Themis_Medicare_a_good_investment_at_Rs_12125\"><\/span><strong>Is Themis Medicare a good investment at Rs 121.25?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> At Rs 121.25, Themis Medicare offers potential upside toward Rs 145 if FY27 earnings recover. Whether this represents a good entry depends on individual risk tolerance. Consult a SEBI registered financial advisor before investing.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_key_risks_to_the_Themis_Medicare_share_price_target_2026\"><\/span><strong>What are the key risks to the Themis Medicare share price target 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Key risks to the Themis Medicare share price target of Rs 145 include FY27 earnings miss, global tariff headwinds, FII outflows, and competitive pressure in Pharmaceutical Formulations and APIs. Monitoring quarterly results is essential.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_52_week_high_and_low_of_Themis_Medicare\"><\/span><strong>What is the 52 week high and low of Themis Medicare?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The 52 week high of Themis Medicare is Rs 199 and the 52 week low is Rs 84. At CMP Rs 121.25, the stock offers potential upside toward the Rs 145 price objective.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_main_growth_catalysts_for_Themis_Medicare_in_2026\"><\/span><strong>What are the main growth catalysts for Themis Medicare in 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Key catalysts include FY27 PAT recovery, Pharmaceutical Formulations and APIs tailwinds, RBI rate cuts in 2026, Budget 2026-27 policy support, and normalisation of FII flows into Indian equities.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_does_Themis_Medicare_compare_to_its_peers\"><\/span><strong>How does Themis Medicare compare to its peers?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Themis Medicare operates in Pharmaceutical Formulations and APIs alongside peers in pharma APIs like Kilitch Drugs and Lincoln Pharmaceuticals. At CMP Rs 121.25 with MCap Rs 605 crore, it is a potential re-rating candidate toward the Themis Medicare share price target of Rs 145 on FY27 delivery.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Themis_Medicare_share_price_target_for_2027\"><\/span><strong>What is the Themis Medicare share price target for 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The long-term Themis Medicare share price target for FY27 to FY28 is Rs 175 in the bull case, assuming earnings growth, sector re-rating, and FII inflows. Consult a SEBI registered financial advisor for personalised guidance.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Themis Medicare share price target 2026 is Rs 145, ~20% upside from CMP Rs 121.25. Bull Rs 175, bear Rs 97. 2026.<\/p>\n","protected":false},"author":28,"featured_media":129529,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802,3972],"class_list":["post-129268","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news","tag-share-price-target"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1782285485:28"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["82"],"rank_math_title":["Themis Medicare Share Price Target 2026: Rs 145 Analyst Forecast"],"rank_math_description":["The Themis Medicare share price target 2026 is Rs 145, ~20% upside from CMP Rs 121.25. Bull Rs 175, bear Rs 97. 2026."],"rank_math_focus_keyword":["Themis Medicare Share Price Target"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"_thumbnail_id":["129529"],"_edit_last":["28"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["20791"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/06\/Themis-Medicare-Share-Price-Target.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/129268","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=129268"}],"version-history":[{"count":2,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/129268\/revisions"}],"predecessor-version":[{"id":129531,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/129268\/revisions\/129531"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/129529"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=129268"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=129268"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=129268"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}